Holen Sie sich die Stockscreener-App
2.40
5.73%
0.13
Handel nachbörslich:
2.40
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio | DEF 14A: Definitive information statements - Moomoo
Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio reports positive cognition data in early Alzheimer’s trial - Investing.com UK
Annovis Bio reports positive cognition data in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio reports positive cognition results in early Alzheimer’s trial By Investing.com - Investing.com Nigeria
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - The Manila Times
Annovis Bio reports positive cognition results in early Alzheimer’s trial - Investing.com
Annovis drug showed cognition gains in early AD; 80% enrolled in Phase 3 - Stock Titan
Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest - MarketBeat
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange - TMX Newsfile
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease - TMX Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) - TMX Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - TMX Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics - TMX Newsfile
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - TMX Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - TMX Newsfile
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile
Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan
Annovis Closes $10 Million Offering, Extending Cash Runway - GlobeNewswire
Annovis Bio Announces $10 Million Underwritten Offering to Advance Alzheimer’s and Parkinson’s Drug Development - Minichart
Annovis Bio Prices Registered Direct Offering to Fund Trials - TipRanks
Annovis Bio Secures ~$10 Million Underwritten Registered Direct Offering With Canaccord Genuity - TradingView
Weekly Trades: Will Annovis Bio Inc. benefit from rising consumer demand2026 Market Trends & Safe Capital Preservation Plans - baoquankhu1.vn
Quarterly Risk: Will Annovis Bio Inc stock hit new highs in YEAR2026 Growth vs Value & Weekly Breakout Watchlists - baoquankhu1.vn
Annovis Bio prices $10M stock offering at $1.90 per share - Investing.com Australia
Annovis Bio (ANVS) launches $10M stock and warrant offering for Phase 3 drug - Stock Titan
Annovis Bio (ANVS) raises ~$10M via 5.26M-share registered direct offering - Stock Titan
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - Bitget
Form 424B5 Annovis Bio, Inc. - StreetInsider
Annovis Bio stock tumbles 26% on dilutive equity offering By Investing.com - Investing.com India
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Annovis Bio stock tumbles 26% on dilutive equity offering - Investing.com
Anovis Bio Inc stock: $10M raise amid Phase 3 push – what it means for you - AD HOC NEWS
Annovis Bio prices $10M stock offering at $1.90 per share By Investing.com - Investing.com South Africa
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):